The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Microtubule-binding agents: a dynamic field of cancer therapeutics
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Self-citationPromotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
Nicolaou, K. C., Yang, Z., Liu, J. J., Ueno, H., Nantermet, P. G., Guy, R. K., Claiborne, C. F., Renaud, J., Couladouros, E. A., Paulvannan, K., et al. (1994) · Nature · doi:10.1038/367630a0 · Cited by 1,096
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.
Jordan, M. A., Toso, R. J., Thrower, D., & Wilson, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9552 · Cited by 1,095
Self-citationDisrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1628 · Cited by 930
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., & Deeley, R. G. (1994) · PubMed · Cited by 770
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., & Poruchynsky, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.27.17118 · Cited by 681
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis
Wahl, A. F., Donaldson, K. L., Faircnild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., & Galloway, D. A. (1996) · Nature Medicine · doi:10.1038/nm0196-72 · Cited by 646
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Targeting Microtubules for Cancer Chemotherapy
Zhou, J., & Giannakakou, P. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053352569 · Cited by 468
Zhou, M., Liu, Z., Zhao, Y., Ding, Y., Liu, H., Xi, Y., Xiong, W., Li, G., Lu, J., Fodstad, O., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083337 · Cited by 424
ROLE OF CHANCE OBSERVATIONS IN CHEMOTHERAPY: VINCA ROSEA*
Noble, R. L., Beer, C. T., & Cutts, J. H. (1958) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1958.tb54906.x · Cited by 407
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
Fromm, M. F. (2000) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38069 · Cited by 399
Beck, W. T., Grogan, T. M., Willman, C. L., Cordon‐Cardo, C., Parham, D. M., Kuttesch, J. F., Andreeff, M., Bates, S. E., Berard, C. W., Boyett, J. M., et al. (1996) · PubMed · Cited by 384
Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5397 · Cited by 341
Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
Mooberry, S. L., Tien, G., Hernandez, A. H., Plubrukarn, A., & Davidson, B. S. (1999) · PubMed · Cited by 324
Direct observation of microtubule dynamics in living cells
Sammak, P. J., & Borisy, G. G. (1988) · Nature · doi:10.1038/332724a0 · Cited by 317
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
Rustin, G. J. S., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.185 · Cited by 307
Paclitaxel Resistance in Non–Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations
Monzó, M., Rosell, R., Sánchez, J. J., Lee, J. S., O'Brate, A., González-Larriba, J. L., Alberola, V., Lorenzo, J. C., Núñez, L., Ro, J. Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1786 · Cited by 306
Stevenson, J. P., Rosen, M., Sun, W., Gallagher, M., Haller, D. G., Vaughn, D., Giantonio, B., Zimmer, R., Petros, W. P., Stratford, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.986 · Cited by 291
Chromosomal instability determines taxane response
Swanton, C., Nicke, B., Schuett, M., Eklund, A. C., Ng, C., Li, Q., Hardcastle, T., Lee, A., Roy, R., East, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811835106 · Cited by 287
The case for survivin as a regulator of microtubule dynamics and cell-death decisions
Altieri, D. C. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.015 · Cited by 284
Tozer, G. M., Prise, V. E., Wilson, J., Čemažar, M., Shan, S., Dewhirst, M. W., Barber, P. R., Vojnovic, B., & Chaplin, D. J. (2001) · PubMed · Cited by 283
Kanthou, C., & Tozer, G. M. (2002) · Blood · doi:10.1182/blood.v99.6.2060 · Cited by 280
Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
Sève, P., & Dumontet, C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70029-9 · Cited by 274
Self-citationPathway Leading to Correctly Folded β-Tubulin
Tian, G., Huang, Y., Rommelaere, H., Vandekerckhove, J., Ampe, C., & Cowan, N. J. (1996) · Cell · doi:10.1016/s0092-8674(00)80100-2 · Cited by 273
How Do Microtubule-Targeted Drugs Work? An Overview
Jordan, M., & Kamath, K. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907783220417 · Cited by 270
Self-citationEvaluation of long-term toxicity after chemotherapy for testicular cancer.
Bokemeyer, C., Berger, C. C., Kuczyk, M. A., & Schmoll, H. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2923 · Cited by 268
Hudes, G. R., Greenberg, R., Krigel, R. L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., Tew, K., & Comis, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.11.1754 · Cited by 256
Lippert, J. W. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.020 · Cited by 247
Vahdat, L. T., Pruitt, B., Fabian, C. J., Rivera, R. R., Smith, D. A., Tan-Chiu, E., Wright, J., Tan, A. R., DaCosta, N. A., Chuang, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7618 · Cited by 244
Peripheral nerve damage associated with administration of taxanes in patients with cancer
Argyriou, A. A., Koltzenburg, M., Polychronopoulos, P., Papapetropoulos, S., & Kalofonos, H. P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.01.008 · Cited by 240
Marsh, S., Paul, J., King, C. R., Gifford, G., McLeod, H. L., & Brown, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4752 · Cited by 238
Buey, R. M., Barasoain, I., Jackson, E., Meyer, A., Giannakakou, P., Paterson, I., Mooberry, S., Andreu, J. M., & Díaz, J. F. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.09.010 · Cited by 231
Kavallaris, M., Tait, A., Walsh, B. J., He, L., Horwitz, S. B., Norris, M. D., & Haber, M. (2001) · PubMed · Cited by 221
Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung Cancer
Gan, P. P., Pasquier, E., & Kavallaris, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0509 · Cited by 221
Ferrandina, G., Zannoni, G. F., Martinelli, E., Paglia, A., Gallotta, V., Mozzetti, S., Scambia, G., & Ferlini, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2715 · Cited by 219
Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
Anderson, H. L., Yap, J. T., Miller, M. P., Robbins, A., Jones, T., & Price, P. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.186 · Cited by 217
Characterization of the azidopine and vinblastine binding site of P-glycoprotein.
Bruggemann, E. P., Currier, S. J., Gottesman, M. M., & Pastan, I. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36791-2 · Cited by 214
Huisman, M. T., Chhatta, A. A., van Tellingen, O., Beijnen, J. H., & Schinkel, A. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.21013 · Cited by 211
Breuninger, L. M., Paul, S., Gaughan, K., Miki, T., Chan, A. M.-L., Aaronson, S. A., & Kruh, G. D. (1995) · PubMed · Cited by 209
Targeting tumour vasculature: the development of combretastatin A4
Griggs, J., Metcalfe, J. C., & Hesketh, R. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00224-2 · Cited by 207
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Okouneva, T., Azarenko, O., Wilson, L., Littlefield, B. A., & Jordan, M. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0095 · Cited by 206
Self-citationBayés, M., Rabasseda, X., & Prous, J. (2002) · PubMed · Cited by 200
Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10)
Hopper-Borge, E., Chen, Z.-S., Shchaveleva, I., Belinsky, M. G., & Kruh, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3111 · Cited by 198
Gridelli, C., Aapro, M., Ardizzoni, A., Balducci, L., De Marinis, F., Kelly, K., Le Chevalier, T., Manegold, C., Perrone, F., Rosell, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.224 · Cited by 196
Gaitanos, T. N., Buey, R. M., Díaz, J. F., Northcote, P. T., Teesdale-Spittle, P., Andreu, J. M., & Miller, J. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0771 · Cited by 193
Fujita, Y., Kojima, K., Ohhashi, R., Hamada, N., Nozawa, Y., Kitamoto, A., Sato, A., Kondo, S., Kojima, T., Deguchi, T., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.079525 · Cited by 192
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.
Alli, E., Bash-Babula, J., Yang, J., & Hait, W. N. (2002) · PubMed · Cited by 187
Bauer, J. A., Chakravarthy, A. B., Rosenbluth, J. M., Mi, D., Seeley, E. H., De Matos Granja-Ingram, N., Olivares, M. G., Kelley, M. C., Mayer, I. A., Meszoely, I. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1091 · Cited by 187
Mooney, C. J., Nagaiah, G., Fu, P., Wasman, J. K., Cooney, M. M., Savvides, P. S., Bokar, J. A., Dowlati, A., Wang, D., Agarwala, S. S., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0321 · Cited by 180
Fan, C.-Y., Cowden, J., Simmons, S. O., Padilla, S., & Ramabhadran, R. (2010) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2009.04.065 · Cited by 179
Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol
Kavallaris, M., Burkhart, C. A., & Horwitz, S. B. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690507 · Cited by 179
Sweeney, C., Liu, G., Yiannoutsos, C., Kolesar, J., Horvath, D., Staab, M. J., Fife, K., Armstrong, V., Treston, A., Sidor, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0440 · Cited by 172
Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines.
Martello, L. A., McDaid, H. M., Regl, D. L., Yang, C. P., Meng, D., Pettus, T. R. R., Kaufman, M. D., Arimoto, H., Danishefsky, S. J., Smith, A. B., et al. (2000) · PubMed · Cited by 166
Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel
Chou, T.-C., Zhang, X.-G., Harris, C. R., Kuduk, S. D., Balog, A., Savin, K. A., Bertino, J. R., & Danishefsky, S. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15798 · Cited by 163
Structural insight into the inhibition of tubulin by vinca domain peptide ligands
Cormier, A., Marchand, M., Ravelli, R. B. G., Knossow, M., & Gigant, B. (2008) · EMBO reports · doi:10.1038/embor.2008.171 · Cited by 162
Hamel, E., Sackett, D. L., Vourloumis, D., & Nicolaou, K. C. (1999) · Biochemistry · doi:10.1021/bi983023n · Cited by 159
Lhommé, C., Joly, F., Walker, J. L., Lissoni, A. A., Nicoletto, M. O., Manikhas, G. M., Baekelandt, M. M. O., Gordon, A. N., Fracasso, P. M., Mietlowski, W. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9807 · Cited by 158
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites
Buey, R. M., Calvo, E., Barasoain, I., Pineda, O., Edler, M. C., Matesanz, R., Cerezo, G., Vanderwal, C. D., Day, B. W., Sorensen, E. J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio853 · Cited by 156
Hari, M., Loganzo, F., Annable, T., Tan, X., Musto, S., Morilla, D. B., Nettles, J. H., Snyder, J. P., & Greenberger, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0190 · Cited by 156
Markman, M. M. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-002-0405-9 · Cited by 153
Shoemaker, A. R., Oleksijew, A., Bauch, J. L., Belli, B., Borre, T., Bruncko, M., Deckwirth, T., Frost, D. J., Jarvis, K., Joseph, M. K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0367 · Cited by 151
Progress in the development and acquisition of anticancer agents from marine sources
Amador, M. L., Jimeno, J. M., Paz-Ares, L. G., Cortés-Funes, H., & Hidalgo, M. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg443 · Cited by 150
Chemoresistance in Non-Small Cell Lung Cancer
Sève, P., & Dumontet, C. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011053352604 · Cited by 149
Self-citationSimoni, D., Grisolia, G., Giannini, G., Roberti, M., Rondanin, R., Piccagli, L., Baruchello, R., Rossi, M., Romagnoli, R., Invidiata, F. P., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049622b · Cited by 149
Stathmin 1: a novel therapeutic target for anticancer activity
Rana, S. R., Maples, P. B., Senzer, N. N., & Nemunaitis, J. J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.9.1461 · Cited by 149
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
Debernardis, D., Siré, E. G., de Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D’Incalci, M., & Broggini, M. (1997) · PubMed · Cited by 146
Haber, M., Burkhart, C. A., Regl, D. L., Madafiglio, J., Norris, M. D., & Horwitz, S. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.52.31269 · Cited by 139
A Unique Mode of Microtubule Stabilization Induced by Peloruside A
Huzil, J. T., Chik, J. K., Slysz, G., Freedman, H., Tuszyński, J. A., Taylor, R. E., Sackett, D. L., & Schriemer, D. C. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.03.026 · Cited by 131
Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth
Landen, J. W., Hau, V. S., Wang, M., Davis, T. P., Ciliax, B. J., Wainer, B. H., Meir, E. G. V., Glass, J. D., Joshi, H. C., & Archer, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0360 · Cited by 130
Hamel, E., Day, B. W., Miller, J. H., Jung, M. K., Northcote, P. T., Ghosh, A. K., Curran, D. P., Cushman, M., Nicolaou, K. C., Paterson, I., et al. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027847 · Cited by 130
Neurological adverse effects caused by cytotoxic and targeted therapies
Schiff, D., Wen, P. Y., & van den Bent, M. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.128 · Cited by 129
Cooney, M. M., Radivoyevitch, T., Dowlati, A., Overmoyer, B. A., Levitan, N. I., Robertson, K., Levine, S. L., DeCaro, K., Buchter, C. M., Taylor, A. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0364-3 · Cited by 129
Synthesis and Biological Evaluation of 4-Arylcoumarin Analogues of Combretastatins. Part 2
Combes, S., Barbier, P., Douillard, S., Leer, A. M., Bourgarel‐Rey, V., Pierson, J., Fedorov, A. Y., Finet, J., Boutonnât, J., & Peyrot, V. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm901826e · Cited by 128
James, J. S., Murry, D. J., Treston, A. M., Storniolo, A. M., Sledge, G. W., Sidor, C. F., & Miller, K. D. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9008-5 · Cited by 128
Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies
Authier, N., Balayssac, D., Marchand, F., Ling, B., Zangarelli, A., Descoeur, J., Coudoré, F., Bourinet, E., & Eschalier, A. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.07.003 · Cited by 125
Synthesis and Biological Evaluation of 4-Arylcoumarin Analogues of Combretastatins
Bailly, C., Bal, C., Barbier, P., Combes, S., Finet, J., Hildebrand, M., Peyrot, V., & Wattez, N. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030903d · Cited by 124
Risinger, A. L., Jackson, E. M., Polin, L., Helms, G. L., LeBoeuf, D. A., Joe, P. A., Hopper-Borge, E. A., Ludueña, R. F., Kruh, G. D., & Mooberry, S. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2037 · Cited by 123
Microtubule Targeting Agents: Basic Mechanisms of Multidrug Resistance (MDR)
Fojo, A. T., & Menefee, M. E. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.010 · Cited by 123
Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies
Tevaarwerk, A. J., Holen, K. D., Alberti, D. B., Sidor, C. F., Arnott, J., Quon, C. Y., Wilding, G., & Liu, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1599 · Cited by 123
Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies
Dumontet, C., Jordan, M. A., & Lee, F. Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0986 · Cited by 112
Self-citationBiochemistry of benzimidazole resistance
Lacey, E., & Gill, J. H. (1994) · Acta Tropica · doi:10.1016/0001-706x(94)90066-3 · Cited by 111
Poruchynsky, M. S., Sackett, D. L., Robey, R. W., Ward, Y., Annunziata, C. M., & Fojo, T. (2008) · Cell Cycle · doi:10.4161/cc.7.7.5625 · Cited by 110
Edelman, M. J. (2003) · Lung Cancer · doi:10.1016/s0169-5002(02)00511-1 · Cited by 109
The Seco-Taxane IDN5390 Is Able to Target Class III β-Tubulin and to Overcome Paclitaxel Resistance
Ferlini, C., Raspaglio, G., Mozzetti, S., Cicchillitti, L., Filippetti, F., Gallo, D., Fattorusso, C., Campiani, G., & Scambia, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3065 · Cited by 107
Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells
Patel, N., Chatterjee, S. K., Vrbanac, V. D., Chung, I., Mu, C. J., Olsen, R. R., Waghorne, C. G., & Zetter, B. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910649107 · Cited by 106
AVE8062: a new combretastatin derivative vascular disrupting agent
Delmonte, A., & Sessa, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903213697 · Cited by 106
Canta, A., Chiorazzi, A., & Cavaletti, G. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787846488 · Cited by 102
Alternative formulations of paclitaxel
Terwogt, J. M. M., Nuijen, B., Huinink, W. W. T. B., & Beijnen, J. H. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90022-0 · Cited by 100
Honoré, S., Kamath, K., Braguer, D., Horwitz, S. B., Wilson, L., Briand, C. M., & Jordan, M. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0693 · Cited by 100
Self-citationBeauregard, D. A., Thelwall, P., Chaplin, D. J., Hill, S., Adams, G., & Brindle, K. M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.294 · Cited by 99
Fan, S., Cherney, B., Reinhold, W. C., Rucker, K., & O'Connor, P. M. (1998) · PubMed · Cited by 97
Total Synthesis of (−)-Laulimalide
Wender, P. A., Hegde, S. G., Hubbard, R. D., & Zhang, L. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0258428 · Cited by 95
Cooper, J. R., Wagenbach, M., Asbury, C. L., & Wordeman, L. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1728 · Cited by 95
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
Tang, P. A., Siu, L. L., Chen, E. X., Hotte, S. J., Chia, S., Schwarz, J. K., Pond, G. R., Johnson, C., Colevas, A. D., Synold, T. W., et al. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9098-8 · Cited by 88
Pusztai, L., Jeong, J., Gong, Y. Y., Ross, J. S., Kim, C., Paik, S., Rouzier, R., André, F., Hortobágyi, G. N., Wolmark, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6887 · Cited by 88
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
Pusztai, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm534 · Cited by 88
In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines
Wagner, M. M. F., Paul, D. C., Shih, C., Jordan, M. A., Wilson, L., & Williams, D. C. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050871 · Cited by 87
Self-citationGapud, E. J., Bai, R., Ghosh, A. K., & Hamel, E. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.113 · Cited by 86
Suppression of centromere dynamics by Taxol in living osteosarcoma cells.
Kelling, J., Sullivan, K. F., Wilson, L., & Jordan, M. A. (2003) · PubMed · Cited by 83
Self-citationBlagden, S. P., Molife, L. R., Seebaran, A., Payne, M., Reid, A. H. M., Protheroe, A. S., Vasist, L., Williams, D. D., Bowen, C. L., Kathman, S. J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604264 · Cited by 82
D’Agostino, G. R., Campo, J.-M. D., Mellado, B., et al. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00276.x · Cited by 82
Galmarini, C. M., Kamath, K., Vanier-Viornery, A., Hervieu, V., Peiller, E.-L., Falette, N., Puisieux, A., Jordan, M. A., & Dumontet, C. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600960 · Cited by 80
Self-citationTeneriello, M. G., Tseng, P. C., Crozier, M., Encarnacion, C. A., Hancock, K. C., Messing, M. J., Boehm, K. A., Williams, A., & Asmar, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9548 · Cited by 80
Genetic Analysis of the -Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer
Kelley, M. J., Li, S., & Harpole, D. H. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1886 · Cited by 80
Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases
Hoffmann, J., Fichtner, I., Lemm, M., Lienau, P., Hess‐Stumpp, H., Rotgeri, A., Hofmann, B., & Klar, U. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-072 · Cited by 79
Stinchcombe, T. E., Socinski, M. A., Walko, C. M., O’Neil, B. H., Collichio, F. A., Ivanova, A., Mu, H., Hawkins, M., Goldberg, R. M., Lindley, C. M., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0423-x · Cited by 79
In Vitro Synergy of Paclitaxel (Taxol) and Vinorelbine (Navelbine) Against Human Melanoma Cell Lines
Photiou, A., Shah, P., Leong, L., Moss, J., & Retsas, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)89023-5 · Cited by 79
Šale, S., Sung, R. K., Shen, P., Yu, K. M., Wang, Y. C., Durán, G. E., Kim, J.-H., Fojo, T., Oefner, P. J., & Sikic, B. I. (2002) · PubMed · Cited by 79
Rajkumar, S. V., Richardson, P. G. G., Lacy, M. Q., Dispenzieri, A. A., Greipp, P. R., Witzig, T. E., Schlossman, R. L., Sidor, C. F., Anderson, K. C., & Gertz, M. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0807 · Cited by 76
Epothilones in the treatment of cancer
Larkin, J., & Kaye, S. B. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.6.691 · Cited by 76
Wienecke-Baldacchino, A. K., & Bacher, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1342 · Cited by 76
Hori, K., Saito, S., & Kubota, K. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600296 · Cited by 75
Cheung, C. H. A., Chen, H.-H., Kuo, C., Chang, C.-Y., Coumar, M. S., Hsieh, H., & Chang, J. Y. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-43 · Cited by 75
Xiao, J. J., Foraker, A. B., Swaan, P. W., Liu, S., Huang, Y. S., Zunyan Dai, Y., Chen, J., Sadée, W., Byrd, J. C., Marcucci, G., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.072033 · Cited by 74
LoRusso, P. M., Gadgeel, S. M., Wozniak, A., Barge, A., Jones, H., DelProposto, Z., DeLuca, P., Evelhoch, J. L., Boerner, S. A., & Wheeler, C. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9112-9 · Cited by 71
Antimitotic Peptides and Depsipeptides
Hamel, E., & Covell, D. G. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354263 · Cited by 70
Geest, K. D., Blessing, J. A., Morris, R. T., Yamada, S., Monk, B. J., Zweizig, S., Matei, D. E., Muller, C. Y., & Richards, W. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1455 · Cited by 70
Azarenko, O., Okouneva, T., Singletary, K. W., Jordan, M. A., & Wilson, L. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn241 · Cited by 68
Self-citationKnox, J. J., Gill, S., Synold, T. W., Biagi, J. J., Major, P. P., Feld, R., Cripps, C., Wainman, N., Eisenhauer, E. A., & Seymour, L. (2008) · Investigational New Drugs · doi:10.1007/s10637-007-9103-2 · Cited by 67
Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1α
Huang, L., Ao, Q., Zhang, Q., Yang, X., Xing, H., Li, F., Chen, G., Zhou, J., Wang, S., Xu, G., et al. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0675-4 · Cited by 67
Hua, J., Sheng, Y., Pinney, K. G., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80778-x · Cited by 66
Ng, S. S. W., Sparreboom, A., Shaked, Y., Lee, C., Man, S., Desai, N. P., Soon‐Shiong, P., Figg, W. D., & Kerbel, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2762 · Cited by 66
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath, D., Discafani, C. M., Loganzo, F., Beyer, C. F., Liu, H., Tan, X., Musto, S., Annable, T., Gallagher, P. A., Rios, C., et al. (2003) · PubMed · Cited by 65
Villanueva, C., Awada, A. H., Campone, M., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.001 · Cited by 65
Yamamoto, K., Noda, K., Yoshimura, A., Fukuoka, M., Furuse, K., & Niitani, H. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050795 · Cited by 64
Development of Novel Chemotherapeutic Agents to Evade the Mechanisms of Multidrug Resistance (MDR)
Lee, J. J., & Swain, S. M. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.013 · Cited by 64
The Tumor Suppressor Protein Fhit
Chaudhuri, A. R., KHAN, I. A., Prasad, V., Robinson, A. K., Ludueña, R. F., & Barnes, L. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24378 · Cited by 63
Larotaxel: broadening the road with new taxanes
Metzger, O., Moulin, C., de Azambuja, E., & Awada, A. H. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903119167 · Cited by 59
Giannakakou, P., Villalba, L., Li, H., Poruchynsky, M. S., & Fojo, T. (1998) · International Journal of Cancer · Cited by 58
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
Al-Katib, A. M., Aboukameel, A., Mohammad, R. M., Bissery, M.-C., & Zuany‐Amorim, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2808 · Cited by 58
Cunningham, C. C., Appleman, L. J., Visovatti, M. A., Ryan, D. P., Regan, E. M., Vukelja, S. J., Bonate, P. L., Ruvuna, F., Fram, R. J., Jekunen, A. P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0058 · Cited by 51
Beer, T. M., Higano, C. S., Saleh, M. N., Dreicer, R., Hudes, G. R., Picus, J., Rarick, M. U., Fehrenbacher, L., & Hannah, A. L. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9068-1 · Cited by 49
Shepard, D. R., Dreicer, R., Garcia, J., Elson, P. J., Magi‐Galluzzi, C., Raghavan, D., Stephenson, A. J., & Klein, E. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2008.11.121 · Cited by 48
Human GTSE-1 Regulates p21CIP1/WAF1 Stability Conferring Resistance to Paclitaxel Treatment
Bublik, D. R., Scolz, M., Triolo, G., Monte, M., & Schneider, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.045948 · Cited by 44
A Neuronal and Astrocyte Co-Culture Assay for High Content Analysis of Neurotoxicity
Anderl, J. L., Redpath, S., & Ball, A. J. (2009) · Journal of Visualized Experiments · doi:10.3791/1173 · Cited by 43
β-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells
Gökmen‐Polar, Y., Escuín, D., Walls, C. D., Soule, S. E., Wang, Y., Sanders, K. L., LaVallee, T. M., Wang, M., Guenther, B. D., Giannakakou, P., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0088 · Cited by 41
Molecular Basis for Class V β-Tubulin Effects on Microtubule Assembly and Paclitaxel Resistance
Bhattacharya, R., & Cabral, F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900167200 · Cited by 40
Biochemical genetic analysis of indanocine resistance in human leukemia.
Hua, X. H., Genini, D., Gussio, R., Tawatao, R. I., Shih, H. A., Kipps, T. J., Carson, D. A., & Leoni, L. M. (2001) · PubMed · Cited by 40
Twelves, C., Loesch, D., Blum, J. L., Vahdat, L. T., Petráková, K., Chollet, P. J. M., Akerele, C., Seegobin, S., Wanders, J., Cortés, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.18_suppl.cra1004 · Cited by 40
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells
Chen, K. G., Durán, G. E., Mangili, A., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1371 · Cited by 39
Meisel, C., Roots, I., Cascorbi, I., Brinkmann, U., & Brockmöller, J. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.126 · Cited by 39
Role of P-glycoprotein in dolastatin 10 resistance
Toppmeyer, D., Slapak, C. A., Croop, J. M., et al. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90292-5 · Cited by 39
Kuttesch, J. F., Parham, D. M., Luo, X., Meyer, W. H., Bowman, L. C., Shapiro, D. N., Pappo, A. S., Crist, W., Beck, W. T., & Houghton, P. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.886 · Cited by 39
Loganzo, F., Hari, M., Annable, T., Tan, X., Morilla, D. B., Musto, S., Zask, A., Kaplan, J. A., Minnick, A. A., May, M. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1319.3.10 · Cited by 39
Shnyder, S. D., Cooper, P. A., Millington, N. J., Pettit, G., & Bibby, M. C. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.2.353 · Cited by 38
Ramanathan, R. K., Picus, J., Raftopoulos, H., Bernard, S. A., Lockhart, A. C., Frenette, G., Macdonald, J. S., Melin, S. A., Berg, D., Brescia, F., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0489-5 · Cited by 37
Tamura, K., Nakagawa, K., Kurata, T., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0382-7 · Cited by 37
Infante, J. R., Yardley, D. A., Burris, H. A., et al. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.004 · Cited by 30
Horti, J., Juhász, E., Monostori, Z., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0665-7 · Cited by 29
Zatloukal, P., Gervais, R., Vansteenkiste, J., Bosquée, L., Sessa, C., Brain, E. G. C., Dansin, É., Urban, T., Dohollou, N., Besenval, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817e6669 · Cited by 27
Baas, P., Szczęsna, A., Albert, I., Milanowski, J., Juhász, E., Sztancsik, Z., von Pawel, J., Oyama, R., & Burgers, S. J. A. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c73ff · Cited by 26
Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly.
Lobert, S., Ingram, J. W., & Correia, J. J. (1999) · PubMed · Cited by 24
Paterson, I., Gardner, N. M., Guzmán, E. A., & Wright, A. E. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.109 · Cited by 23
Akashi, Y., Okamoto, I., Suzuki, M., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603769 · Cited by 20
Re: Genetic Analysis of the beta-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer
Šale, S. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.10.776 · Cited by 16
Phase II Trial of Intravenous CI-980 (NSC 370147) in Patients with Metastatic Colorectal Carcinoma
Pazdur, R., Meyers, C., Diaz-Canton, E. A., Abbruzzese, J. L., Patt, Y. Z., Grove, W. R., & Ajani, J. A. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199712000-00008 · Cited by 14
Gertsch, J., Feyen, F., Bützberger, A., Gerber, B., Pfeiffer, B., & Altmann, K. (2009) · ChemBioChem · doi:10.1002/cbic.200900376 · Cited by 13
William, W. N., Khuri, F. R., Fossella, F. V., Glisson, B. S., Zinner, R., Lee, J. J., Herbst, R. S., Lippman, S. M., & Kim, E. S. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318199fb99 · Cited by 10
Abstract 4438: Comparison of neuropathy-inducing effects of eribulin versus paclitaxel in mice
Wozniak, K. M., Lapidus, R. G., Wu, Y., Carozzi, V., Cavaletti, G., Hayakawa, K., Hosokawa, S., Towle, M. J., Littlefield, B. A., Nomoto, K., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-4438 · Cited by 2
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Self-citationChalcone: A Privileged Structure in Medicinal Chemistry
Zhuang, C., Zhang, W., Sheng, C., Zhang, W., Xing, C., & Miao, Z. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00020 · Cited by 1,463
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Control of microtubule organization and dynamics: Two ends in the limelight
Akhmanova, A., & Steinmetz, M. O. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4084 · Cited by 895
Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.01.066 · Cited by 849
Metadata
- Authors
- Dumontet, C., & Jordan, M. A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-10
- Volume
- 9
- Issue
- 10
- Pages
- 790-803
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2093855538
- Cited by
- 1,718
- References
- 169
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.